Pharmacovigilance & Drug Safety Software Market by Product (Adverse Event Reporting Software, Drug Safety Audits Software, Fully Integrated Software), Clinical Trial (Phase I, Phase II, Phase III), Distribution, End User - Global Forecast 2024-2030
Description
Pharmacovigilance & Drug Safety Software Market by Product (Adverse Event Reporting Software, Drug Safety Audits Software, Fully Integrated Software), Clinical Trial (Phase I, Phase II, Phase III), Distribution, End User - Global Forecast 2024-2030
The Pharmacovigilance & Drug Safety Software Market size was estimated at USD 552.10 million in 2023 and expected to reach USD 629.31 million in 2024, at a CAGR 14.55% to reach USD 1,429.24 million by 2030.
The pharmacovigilance & drug safety software encompasses a range of digital platforms designed to monitor, assess, understand, and prevent adverse effects or other drug-related problems. These software solutions are employed by pharmaceutical and biotechnology companies, contract research organizations (CROs), regulatory agencies, and others integral to the drug development process and post-marketing surveillance. The primary aim is to ensure compliance with global regulatory standards, streamline reporting processes, and improve patient safety outcomes. The expanding pharmaceutical industry with the rising development of novel drugs is raising the need for pharmacovigilance & drug safety software. The growing adoption of digital technologies with the need for efficient data management systems in the face of growing data volumes is driving the market growth. Data security and privacy issues associated with pharmacovigilance and drug safety software hamper the market growth. Rising investments in advanced analytics capabilities to transform raw data into actionable insights for better risk management and creating intuitive UI/UX designs that enable efficient workflow management and ease of use, even for non-technical users, are expected to create opportunities for market growth.
Regional Insights
Encompassing both North and South America, the region demonstrates a significant demand for pharmacovigilance & drug safety software largely driven by stringent regulations and a sophisticated healthcare infrastructure. The Americas leads in terms of adoption of technology, investment in R&D, and implementation of regulations to ensure drug safety. Canada follows with a robust healthcare system and a growing focus on pharmacovigilance. The European Union, with its harmonized regulations through the EMA (European Medicines Agency), presents a growing market for pharmacovigilance (PV) & drug safety software. EU countries have seen increasing adoption of PV software solutions to comply with adverse drug reaction (ADR) reporting, risk management plan requirements, and pharmacovigilance audit strategies as mandated by the EMA. The MEA region shows varied levels of adoption, with certain countries exhibiting increased growth in pharmacovigilance due to rising healthcare standards and government initiatives to regulate drugs more effectively. Comprising major economies such as China, India, and Japan, the Asia Pacific region is rapidly emerging as a key market for PV software solutions with the rising healthcare spending, increasing awareness about drug safety, and growing pharmaceutical sectors contributing to the expansion of the pharmacovigilance software market in this region.
Market Insights
- Market Dynamics
The market dynamics represent an ever-changing landscape of the Pharmacovigilance & Drug Safety Software Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.- Market Drivers
- Rising Incidence of ADR and Drug Toxicity
- Increasing Need to Reduce Time Spent Reviewing Medical Literature for Aggregate Reports and Articles
- Highly Regulated Pharmacovigilance Space
- Market Restraints
- Expensive Deployment of Pharmacovigilance & Drug Safety Software
- Market Opportunities
- Increasing Investment in Research and Development (R&D) by Healthcare Companies
- Integration of AI and Machine Learning Models in Pharmacovigilance & Drug Safety Software
- Market Challenges
- Lack of Awareness, Training, and Underreporting of Adverse Drug Reactions (ADRs) in Developing Countries
- Market Segmentation Analysis
- Product: Growing usage of drug safety audit software to ensure compliance with pharmacovigilance regulations
- End User: Potential of pharmacovigilance & drug safety software among contract research organizations for handling clinical trial data and offering advanced reporting capabilities
- Market Disruption Analysis
- Porter’s Five Forces Analysis
- Value Chain & Critical Path Analysis
- Pricing Analysis
- Technology Analysis
- Patent Analysis
- Trade Analysis
- Regulatory Framework Analysis
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Pharmacovigilance & Drug Safety Software Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Pharmacovigilance & Drug Safety Software Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments- RxLogix Corporation Announces Landmark Partnership with the European Medicines Agency (EMA) for a Cutting-Edge Safety Solution
RxLogix Corporation announced its strategic partnership with the European Medicines Agency (EMA). This collaboration would spearhead the creation of a pioneering Signal and Safety Analytics (SSA) platform, enhancing the capability and efficiency of signal detection and validation procedures for the Agency and the European Medicines Regulatory Network (EMRN). The platform integrates the robust features of RxLogix PV Signal for efficient data mining and analytics, PV Reports for advanced regulatory compliance, and PV Analytics for detailed data examination and visualization, streamlining the processes to ensure optimal regulatory authority support.
Launch by JNPMEDI of 'Maven Safety,' a drug safety management solution
JNPMEDI unveiled a groundbreaking drug safety management tool, Maven Safety. Tailored to bridge the affordability gap in pharmacovigilance software, this innovative platform operates on a subscription-based SaaS model, allowing users to customize their experience by selecting only the features necessary for their project scale. Maven Safety promises to revolutionize drug safety management for small to mid-sized firms by offering a cost-effective, user-friendly solution that adheres to international standards without the need for expensive installations.
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Pharmacovigilance & Drug Safety Software Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Pharmacovigilance & Drug Safety Software Market, highlighting leading vendors and their innovative profiles. These include 4C Pharma Solutions, AB Cube S.A.S., Accenture PLC, Anju Software, Inc., ArisGlobal LLC, Certara, Inc., Clarivate, Clinevo Technologies Private Limited, Cloudbyz, Inc., Cognizant Technology Solutions Corporation, Ennov SAS, Ergomed PLC, Extedo GmbH, Freyr Software Services Pvt. Ltd., Indegene Inc., Infosys Limited, IQVIA Inc., NUVO Consultancy, Oracle Corporation, PureSoftware Limited, Sarjen Systems Private Limited, Sparta Systems, Inc., Tepsivo Oy, TriNetX, LLC, United BioSource LLC, and Wipro Limited.
Market Segmentation & Coverage
This research report categorizes the Pharmacovigilance & Drug Safety Software Market to forecast the revenues and analyze trends in each of the following sub-markets:- Product
- Adverse Event Reporting Software
- Drug Safety Audits Software
- Fully Integrated Software
- Issue Tracking Software
- Clinical Trial
- Phase I
- Phase II
- Phase III
- Phase IV
- Pre-clinical
- Distribution
- On-Cloud
- On-Premise
- End User
- Business Process Outsourcing Firms
- Contract Research Organizations
- Pharma & Biotech Companies
- Pharmacovigilance Service Providers
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
Please Note: PDF & Excel + Online Access - 1 Year
- Americas
- Market Drivers
Table of Contents
187 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Rising Incidence of ADR and Drug Toxicity
- 5.1.1.2. Increasing Need to Reduce Time Spent Reviewing Medical Literature for Aggregate Reports and Articles
- 5.1.1.3. Highly Regulated Pharmacovigilance Space
- 5.1.2. Restraints
- 5.1.2.1. Expensive Deployment of Pharmacovigilance & Drug Safety Software
- 5.1.3. Opportunities
- 5.1.3.1. Increasing Investment in Research and Development (R&D) by Healthcare Companies
- 5.1.3.2. Integration of AI and Machine Learning Models in Pharmacovigilance & Drug Safety Software
- 5.1.4. Challenges
- 5.1.4.1. Lack of Awareness, Training, and Underreporting of Adverse Drug Reactions (ADRs) in Developing Countries
- 5.2. Market Segmentation Analysis
- 5.2.1. Product: Growing usage of drug safety audit software to ensure compliance with pharmacovigilance regulations
- 5.2.2. End User: Potential of pharmacovigilance & drug safety software among contract research organizations for handling clinical trial data and offering advanced reporting capabilities
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of Russia-Ukraine Conflict
- 5.5. Cumulative Impact of High Inflation
- 5.6. Porter’s Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
- 5.7. Value Chain & Critical Path Analysis
- 5.8. Regulatory Framework Analysis
- 5.9. Client Customization
- 6. Pharmacovigilance & Drug Safety Software Market, by Product
- 6.1. Introduction
- 6.2. Adverse Event Reporting Software
- 6.3. Drug Safety Audits Software
- 6.4. Fully Integrated Software
- 6.5. Issue Tracking Software
- 7. Pharmacovigilance & Drug Safety Software Market, by Clinical Trial
- 7.1. Introduction
- 7.2. Phase I
- 7.3. Phase II
- 7.4. Phase III
- 7.5. Phase IV
- 7.6. Pre-clinical
- 8. Pharmacovigilance & Drug Safety Software Market, by Distribution
- 8.1. Introduction
- 8.2. On-Cloud
- 8.3. On-Premise
- 9. Pharmacovigilance & Drug Safety Software Market, by End User
- 9.1. Introduction
- 9.2. Business Process Outsourcing Firms
- 9.3. Contract Research Organizations
- 9.4. Pharma & Biotech Companies
- 9.5. Pharmacovigilance Service Providers
- 10. Americas Pharmacovigilance & Drug Safety Software Market
- 10.1. Introduction
- 10.2. Argentina
- 10.3. Brazil
- 10.4. Canada
- 10.5. Mexico
- 10.6. United States
- 11. Asia-Pacific Pharmacovigilance & Drug Safety Software Market
- 11.1. Introduction
- 11.2. Australia
- 11.3. China
- 11.4. India
- 11.5. Indonesia
- 11.6. Japan
- 11.7. Malaysia
- 11.8. Philippines
- 11.9. Singapore
- 11.10. South Korea
- 11.11. Taiwan
- 11.12. Thailand
- 11.13. Vietnam
- 12. Europe, Middle East & Africa Pharmacovigilance & Drug Safety Software Market
- 12.1. Introduction
- 12.2. Denmark
- 12.3. Egypt
- 12.4. Finland
- 12.5. France
- 12.6. Germany
- 12.7. Israel
- 12.8. Italy
- 12.9. Netherlands
- 12.10. Nigeria
- 12.11. Norway
- 12.12. Poland
- 12.13. Qatar
- 12.14. Russia
- 12.15. Saudi Arabia
- 12.16. South Africa
- 12.17. Spain
- 12.18. Sweden
- 12.19. Switzerland
- 12.20. Turkey
- 12.21. United Arab Emirates
- 12.22. United Kingdom
- 13. Competitive Landscape
- 13.1. Market Share Analysis, 2023
- 13.2. FPNV Positioning Matrix, 2023
- 13.3. Competitive Scenario Analysis
- 13.3.1. RxLogix Corporation Announces Landmark Partnership with the European Medicines Agency (EMA) for a Cutting-Edge Safety Solution
- 13.3.2. Launch by JNPMEDI of 'Maven Safety,' a drug safety management solution
- 14. Competitive Portfolio
- 14.1. Key Company Profiles
- 14.2. Key Product Portfolio
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
